Resorptive potential of systemic enzyme therapy: a differentiated approach to the treatment of cystic formations in the practice of an obstetrician-gynecologist | Ukrainian Medical Journal

Lastovetska O.B.

Main
Publications
Resorptive potential of systemic enzyme therapy: a differentiated approach to the treatment of cystic formations in the practice of an obstetrician-gynecologist

Resorptive potential of systemic enzyme therapy: a differentiated approach to the treatment of cystic formations in the practice of an obstetrician-gynecologist

June 18, 2026

Obstetrics and Gynecology

Lastovetska O.B.

УДК: 618.14-006.2+618.14-005.1

DOI: 10.32471/umj.1680-3051.278045

Keywords :

adhesive disease,

ERAS protocols,

fibrinolysis,

functional ovarian cysts,

Movinaza,

serratiopeptidase,

systemic enzyme therapy

Specialities :

Obstetrics and Gynecology

Resume

The article presents a comprehensive pathogenetic analysis and systematization of modern scientific data on the use of systemic enzyme therapy, in particular the highly selective proteolytic enzyme serratiopeptidase (using the example of the drug Movinaza), in modern obstetric and gynecological practice. The molecular mechanisms of action of the enzyme, which include fibrinolytic, anti-edematous, anti-inflammatory and COX-independent analgesic vectors, are substantiated. Special attention is paid to a differentiated approach and phase-dependent safety monitoring in the management of patients with benign functional ovarian cysts, tubo-ovarian formations of inflammatory genesis. Integration of the drug Movinaza into complex treatment regimens and ERAS protocols allows reducing the risk of postoperative adhesiogenesis, preventing the chronicity of pelvic pain and increasing the effectiveness of concomitant antibacterial therapy due to the destruction of bacterial biofilms.

References

1. Franco P.N., García-Baizán A., Aymerich M. et al. (2023) Gynaecological Causes of Acute Pelvic Pain: Common and Not-So-Common Imaging Findings. Life. 2025. DOI: 10.3390/life13102025.
2. Nelson G., Fotopoulou C., Taylor J. et al. (2023) Enhanced recovery after surgery (ERAS^®) society guidelines for gynecologic oncology: Addressing implementation challenges — 2023 update. Gynecologic Oncology, 58–67. DOI: 10.1016/j.ygyno.2023.04.009.
3. Alkatout I., De Wilde R.L., Herrmann J. et al. (2024) Adhesion Prevention in Gynecologic Surgery: Guidance and Clinical Experience. J. Clin. Med., 7517. DOI: 10.3390/jcm13247517.
4. Fazel Anvari-Yazdi A., MacPhee D.J., Badea I. et al. (2025) Gynecologic postoperative anti-adhesion barriers: From biomaterials to barrier development. Biomaterials and Biosystems, 100115. DOI: 10.1016/j.bbiosy.2025.100115.
5. Tiwari M. (2017) The role of serratiopeptidase in the resolution of inflammation. Asian J. Pharmaceut. Sci., 209–215. DOI: 10.1016/j.ajps.2017.01.003.
6. Jadhav S.B., Shah N., Rathi A. et al. (2020) Serratiopeptidase: Insights into the therapeutic applications. Biotechnol. Rep., e00544. DOI: 10.1016/j.btre.2020.e00544.
7. Мовіназа^® 10 мг (серратіопептидаза) (2026) Інструкція для медичного застосування лікарського засобу. Державний реєстр лікарських засобів України.
8. Мовіназа^® 20 мг (серратіопептидаза) (2026) Інструкція для медичного застосування лікарського засобу. Державний реєстр лікарських засобів України.
9. Nair S.R., Subathra D.C. (2022) Serratiopeptidase: An Integrated View of Multifaceted Therapeutic Enzyme. Biomolecules, 1468. DOI: 10.3390/biom12101468.
10. Bhagat S., Agarwal M., Roy V. (2013) Serratiopeptidase: a systematic review of the existing evidence. Int. J. Surg., 209–217. DOI: 10.1016/j.ijsu.2013.01.010.
11. Mazzone A., Catalani M., Costanzo M. et al. (1990) Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J. Int. Med. Res., 18(5): 379–388. DOI: 10.1177/030006059001800506.
12. Sivaramakrishnan G., Sridharan K. (2018) Role of Serratiopeptidase After Surgical Removal of Impacted Molar: A Systematic Review and Meta-analysis. J. Maxillofacial Oral Surg., 17: 122–128. DOI: 10.1007/s12663-017-0996-9.
13. Bapat K., Kumar A., Katke P. et al. (2024) Serratiopeptidase with diclofenac sodium for the management of post-operative pain and inflammation in a day care obstetric and gynaecological surgeries. Indian J. Obstetr. Gynecol. Res., 11(3): 442–446. DOI: 10.18231/j.ijogr.2024.080.
14. Diamond M.P., Freeman M.L. (2001) Clinical implications of postsurgical adhesions. Human Reproduction Update, 7(6): 567–576. DOI: 10.1093/humupd/7.6.567.
15. Sharma C., Jha N.K., Meeran M.F.N. et al. (2021) Serratiopeptidase, A Serine Protease Anti-Inflammatory, Fibrinolytic, and Mucolytic Drug, Can Be a Useful Adjuvant for Management in COVID-19. Front. Pharmacol., 12: 603997. DOI: 10.3389/fphar.2021.603997.
16. Revzin M.V., Mathur M., Dave H.B. et al. (2016) Pelvic Inflammatory Disease: Multimodality Imaging Approach with Clinical-Pathologic Correlation. Radiographics, 36(5): 1579–1596. DOI: 10.1148/rg.2016150202.
17. Ang C.J., Skokan T.D., McKinley K.L. (2023) Mechanisms of Regeneration and Fibrosis in the Endometrium. Annual Review of Cell and Developmental Biology, 39: 197–221. DOI: 10.1146/annurev-cellbio-011723-021442.
18. Міністерство охорони здоров’я України (2023) Про затвердження Стандартів медичної допомоги «Запальні захворювання органів малого таза» (наказ № 928). moz.gov.ua/uk/decrees/nakaz-moz-ukraini-vid-18052023–928-pro-zatverdzhennja-standartiv-medichnoi-dopomogi-zapalni-zahvorjuvannja-organiv-malogo-taza.
19. Ross J., Cole M., Evans C. et al. (2018) 2018 United Kingdom National Guideline for the Management of Pelvic Inflammatory Disease. British Association for Sexual Health and HIV (BASHH). bashh.org.
20. Centers for Disease Control and Prevention. (2021) Sexually transmitted infections treatment guidelines, 2021: Pelvic inflammatory disease (PID). U.S. Department of Health and Human Services. cdc.gov.
21. Kairys N., Roepke C. (2024) Tubo-Ovarian Abscess. StatPearls (Internet). NCBI Bookshelf. NBK448125.
22. Rajaram P., Bhattacharjee A., Ticku S. (2016) Serratiopeptidase — A Cause for Spread of Infection. J. Clin. Diagnost. Res., 10(8): ZD31–2. DOI: 10.7860/JCDR/2016/21388.8302.
23. Napoletano I. (2021) Serrapeptase for use in the treatment of deep endometriosis. European Patent Application. EP3815710A1.